HaTay Pharmaceutical JSC

HaTay Pharmaceutical JSC Liabilities

The The Liabilities of HaTay Pharmaceutical JSC (DHT.VN) as of Nov 2, 2026 is 896.76 B VND. In the previous year, The Liabilities was 799.99 B VND — a change of 12.10% (higher).

Liabilities

896.76 BVND

YoY

12.10%

Last updated:

In 2024, HaTay Pharmaceutical JSC's total liabilities amounted to 896.76 B VND, a 12.10% difference from the 799.99 B VND total liabilities in the previous year.

The HaTay Pharmaceutical JSC Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2017
406.73 B VND
Jan 1, 2018
389.28 B VND
Jan 1, 2019
449.49 B VND
Jan 1, 2020
593.82 B VND
Jan 1, 2021
507.83 B VND
Jan 1, 2022
696.16 B VND
Jan 1, 2023
799.99 B VND
Jan 1, 2024
896.76 B VND
The HaTay Pharmaceutical JSC Liabilities history
YEARLiabilitiesYoY
896.76 BVND+12.10%
799.99 BVND+14.91%
696.16 BVND+37.09%
507.83 BVND-14.48%
593.82 BVND+32.11%
449.49 BVND+15.47%
389.28 BVND-4.29%
406.73 BVND+20.45%
337.67 BVND+15.33%
292.80 BVND+27.99%
228.77 BVND—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

HaTay Pharmaceutical JSC Stock analysis

What does HaTay Pharmaceutical JSC do? Ha Tay Pharmaceutical JSC generates revenue through the manufacturing, import, and export of pharmaceuticals, cosmetics, and medical equipment. The company sells its products via wholesale and retail channels, targeting healthcare providers, pharmacies, and consumers. It also engages in the production and trading of cosmetic products, supplemental food, and laboratory chemicals, alongside medical equipment and supplies. The firm completed the acquisition of a 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company in 2013, expanding its market presence in pharmaceuticals and medical equipment. The company operates in the pharmaceutical sector, serving healthcare institutions, retail pharmacies, and end consumers. Its revenue streams include the sale of drugs, cosmetics, medical equipment, and related supplies. Additional income comes from supermarket operations, real estate leasing, and vocational training services, though these are secondary to its core pharmaceutical business. Ha Tay Pharmaceutical JSC's primary customers are healthcare providers, pharmacies, and consumers purchasing pharmaceuticals, cosmetics, and medical equipment. The firm's product portfolio spans drugs, vaccines, cosmetic products, supplemental food, and laboratory chemicals, with a focus on manufacturing and trading. The acquisition of the 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company has strengthened its position in the medical equipment market. HaTay Pharmaceutical JSC is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing HaTay Pharmaceutical JSC's Liabilities

HaTay Pharmaceutical JSC's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating HaTay Pharmaceutical JSC's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing HaTay Pharmaceutical JSC's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

HaTay Pharmaceutical JSC's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in HaTay Pharmaceutical JSC’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about HaTay Pharmaceutical JSC stock

The Liabilities of HaTay Pharmaceutical JSC is 896.76 B VND in 2024.

The Liabilities of HaTay Pharmaceutical JSC changed from 799.99 B VND to 896.76 B VND, representing a 12.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities HaTay Pharmaceutical JSC since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's VND is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's HaTay Pharmaceutical JSC historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — HaTay Pharmaceutical JSC

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — HaTay Pharmaceutical JSC